Results 1 to 10 of about 1,428 (167)

Effects of short‐term tofogliflozin treatment on the insulin secretory capacity of people with type 2 diabetes: A randomized controlled trial, the TOP‐ELM study [PDF]

Journal of Diabetes Investigation
Aims/Introduction We aimed to explore the short‐term effects of tofogliflozin on the insulin secretory capacity of people with type 2 diabetes. Materials and Methods We performed a multicenter, prospective, randomized, active‐controlled, open‐label ...
Maiko Miyamoto, Aika Miya, Akinobu Nakamura, Yuka Takahashi, Yuki Yamauchi, Shingo Yanagiya, Takahiro Takase, Mayuko Ono, Kiyohiko Takahashi, Kazufumi Okada, Hiraku Kameda, Kyu Yong Cho, Tatsuya Atsumi, TOP‐ELM study group   +13 more
doaj   +3 more sources

Effect of administration and withdrawal of the sodium‐glucose cotransporter 2 inhibitor, tofogliflozin, on renal protection in individuals with type 2 diabetes mellitus and diabetic nephropathy: A multicenter, single‐arm study (RESTORE‐nephropathy study) [PDF]

Journal of Diabetes Investigation
Aims/Introduction The mechanisms of the renoprotective effects of sodium‐glucose cotransporter 2 inhibitors are unknown. This study aimed to explore the effect and mechanism of tofogliflozin on urinary albumin by administration, withdrawal, and re ...
Ayako Shigeta, Masami Tanaka, Shu Meguro, Jiro Morimoto, Takatoshi Imai, Akira Yamauchi, Yasuhiko Kanazawa, Toshihide Kawai, Koichiro Azuma, Satoru Yamada, Sho Endo, Hiroshi Itoh, Kaori Hayashi   +12 more
doaj   +3 more sources

Multicenter, open label, randomized controlled superiority trial for availability to reduce nocturnal urination frequency: The TOP‐STAR study [PDF]

Journal of Diabetes Investigation
Aim Nocturia impairs the quality of life in patients with type 2 diabetes mellitus. Although sodium glucose co‐transporter 2 inhibitors (SGLT2i) such as tofogliflozin increase urine volume, their impact on nocturia, in conjunction with dietary salt ...
Hanako Nakajima, Hiroshi Okada, Akinori Kogure, Takafumi Osaka, Takeshi Tsutsumi, Masayoshi Onishi, Kazuteru Mitsuhashi, Noriyuki Kitagawa, Shinichi Mogami, Akane Kitamura, Michiyo Ishii, Naoto Nakamura, Akio Kishi, Sato Eiko, Masahide Hamaguchi, Michiaki Fukui   +15 more
doaj   +3 more sources

Distinct metabolomic signatures of SGLT2 inhibitor vs. sulfonylurea in a paired human liver biopsy study [PDF]

Biochemistry and Biophysics Reports
This study aimed to elucidate how sodium-glucose cotransporter 2 (SGLT2) inhibitors and sulfonylureas differentially modulate hepatic metabolism in persons with metabolic dysfunction-associated steatotic liver disease (MASLD) and type 2 diabetes (T2D).In
Yumie Takeshita, Hein Ko Oo, Yujiro Nakano, Ayano Ueno, Maki Oishi, Hiromasa Tsujiguchi, Tomoyoshi Soga, Taro Yamashita, Masao Honda, Toshinari Takamura   +9 more
doaj   +2 more sources

Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus: Results of 24-month interim analysis of a long-term post-marketing study (J-STEP/LT)

Journal of Diabetes Investigation, 2020
Aims/Introduction Tofogliflozin is a potent and highly selective sodium–glucose cotransporter 2 inhibitor, and is currently used to treat patients with type 2 diabetes mellitus. We designed a 3‐year study of tofogliflozin in patients with type 2 diabetes
Masayuki Senda, Seigo Kakiuchi, Yuji Kurihara   +2 more
exaly   +2 more sources

Safety and efficacy of tofogliflozin in Japanese patients with type 2 diabetes mellitus in real-world clinical practice: Results of 3-month interim analysis of a long-term post-marketing surveillance study (J-STEP/LT)

Journal of Diabetes Investigation, 2019
Aims/Introduction The present study analysis was carried out to evaluate the safety and efficacy of tofogliflozin, a sodium–glucose cotransporter 2 inhibitor, in Japanese patients with type 2 diabetes mellitus in real‐world clinical practice.
Masayuki Senda, Hisataka Fujiwara, Seigo Kakiuchi   +2 more
exaly   +2 more sources

Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus in real-world practice: Results of 12-month interim analysis of a long-term post-marketing surveillance study (J-STEP/LT)

Journal of Diabetes Investigation, 2020
Aims/Introduction Due to the paucity of tofogliflozin data, we assessed the safety and effectiveness of tofogliflozin among Japanese patients with type 2 diabetes mellitus in the clinical setting, stratifying the patients by age, sex, estimated ...
Masayuki Senda, Seigo Kakiuchi, Yuji Kurihara   +2 more
exaly   +2 more sources

The effects of 12-month administration of tofogliflozin on electrolytes and dehydration in mainly elderly Japanese patients with type 2 diabetes mellitus

Journal of International Medical Research, 2018
Objective To assess the effect of 12 months of treatment with tofogliflozin on electrolytes and dehydration in Japanese patients with type 2 diabetes mellitus (T2DM) Methods This retrospective study involved mainly elderly patients with T2DM who had ...
Masashi Okuro, Toshihiro Higashikawa, Tomohiko Itô   +2 more
exaly   +2 more sources

Effect of tofogliflozin on cardiac sympathetic nerve activity in type 2 diabetes mellitus patients with heart failure (TARGET-HF): rationale and design of the single-arm intervention trial [PDF]

Cardiovascular Diabetology. Endocrinology Reports
Background Cardiac sympathetic nervous dysfunction is linked to poor prognosis in heart failure with reduced ejection fraction (HFrEF), and patients with HFrEF complicated by type 2 diabetes mellitus (T2DM) represent a particularly high risk.
Takahiro Okumura, Yasuko K Bando, Satoshi Isobe, Naotoshi Fujita, Fusako Sera, Yuki Ikeda, Ayumu Yajima, Toshiyuki Nagai, Hiroaki Hiraiwa, Ryota Morimoto, Toshihisa Anzai, Koichi Node, Junya Ako, Yasushi Sakata, Toyoaki Murohara   +14 more
doaj   +2 more sources

Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus treated in real-world clinical practice: Results of a 36-month post-marketing surveillance study (J-STEP/LT)

Journal of Diabetes Investigation, 2021
Aims/Introduction Tofogliflozin is a sodium–glucose cotransporter 2 (SGLT2) inhibitor that lowers plasma glucose levels by enhancing urinary glucose excretion.
Masayuki Senda, Seigo Kakiuchi, Yuji Kurihara   +2 more
exaly   +2 more sources